Literature DB >> 19194904

Physicochemical characterization of siRNA-peptide complexes.

Maggie Law1, Mousa Jafari, P Chen.   

Abstract

Short interfering RNAs (siRNAs) trigger RNA interference (RNAi), where the complementary mRNA is degraded, resulting in silencing of the encoded protein. A delivery carrier is desired to increase the solution stability of siRNA and improve its cellular uptake to overcome its rapid enzymatic degradation and low transfection efficiency. In this study, Arginine-9 (R9), a cell-penetrating peptide derived from the HIV 1 Tat protein, was investigated as a potential carrier for siRNAs. A connective tissue growth factor (CTGF) encoding siRNA was used because of its therapeutic potential of treating breast cancer. The interaction between R9 and siRNA was studied by UV/vis spectroscopy and circular dichroism (CD). The hydrodynamic diameter of the siRNA-R9 complexes was determined by dynamic light scattering (DLS), and the Zeta potential of the complexes was obtained by measuring the electrophoretic mobility. The effect of salt addition is also quantified using UV-vis spectroscopy. The siRNA and R9 readily formed complexes/aggregates through molecular association, accompanying a change in surface charge with increasing peptide concentration, reaching a maximum hydrodynamic diameter of approximately 1 mum at siRNA saturation. The highest binding ratio of R9 to siRNA determined from the UV/vis spectra and CD is 10.3:1 and 39.1:1 from DLS (corresponds to charge ratios of 2.2:1 (+/-) and 8.4:1, respectively). The difference in binding ratio is possibly because of the difference in signal contribution between absorption and light scattering. The physicochemical characterization of CTGF siRNA-R9 complexes presented here have shown that various methods can be used to control the properties of the siRNA-peptide complexes, which provide a basis for the formulation of siRNA therapeutics with peptide carriers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19194904     DOI: 10.1002/btpr.13

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  8 in total

1.  Non-covalent Encapsulation of siRNA with Cell-Penetrating Peptides.

Authors:  Martina Tuttolomondo; Henrik J Ditzel
Journal:  Methods Mol Biol       Date:  2021

2.  Helical Poly(arginine) Mimics with Superior Cell-Penetrating and Molecular Transporting Properties.

Authors:  Haoyu Tang; Lichen Yin; Kyung Hoon Kim; Jianjun Cheng
Journal:  Chem Sci       Date:  2013-10       Impact factor: 9.825

3.  Oligonucleotide Probe for Transcriptome in Vivo Analysis (TIVA) of Single Neurons with Minimal Background.

Authors:  Sean B Yeldell; Linlin Yang; Jaehee Lee; James H Eberwine; Ivan J Dmochowski
Journal:  ACS Chem Biol       Date:  2020-09-23       Impact factor: 5.100

Review 4.  Concepts in in vivo siRNA delivery for cancer therapy.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  J Cell Physiol       Date:  2009-08       Impact factor: 6.384

Review 5.  Non-viral nanocarriers for siRNA delivery in breast cancer.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

6.  Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo.

Authors:  Yan Wu; Parisa Sadatmousavi; Rong Wang; Sheng Lu; Yong-fang Yuan; P Chen
Journal:  Int J Nanomedicine       Date:  2012-06-28

7.  Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery.

Authors:  Martina Tuttolomondo; Cinzia Casella; Pernille Lund Hansen; Ester Polo; Luciana M Herda; Kenneth A Dawson; Henrik J Ditzel; Jan Mollenhauer
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-29       Impact factor: 8.886

Review 8.  Delivery of therapeutic oligonucleotides with cell penetrating peptides.

Authors:  Prisca Boisguérin; Sébastien Deshayes; Michael J Gait; Liz O'Donovan; Caroline Godfrey; Corinne A Betts; Matthew J A Wood; Bernard Lebleu
Journal:  Adv Drug Deliv Rev       Date:  2015-03-04       Impact factor: 15.470

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.